<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771366</url>
  </required_header>
  <id_info>
    <org_study_id>00005695 -rev. comments</org_study_id>
    <nct_id>NCT02771366</nct_id>
  </id_info>
  <brief_title>The Efficient Brain Study</brief_title>
  <official_title>The Influence of Fermented Papaya Preparation (FPP) on Cerebral Energy Metabolism, Neuroinflammation, and Cognition in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osato Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral energy metabolism declines with advanced aging, and is implicated in age-related
      cognitive decline, Alzheimer's disease (AD), and other forms of neurodegenerative disease
      (Parkinson's disease). In addition, age-associated increase in systemic and neuroinflammation
      is associated with a higher likelihood for development of Alzheimer's disease and
      neurodegenerative disease in older adults. Furthermore, decreased cerebral energy metabolism
      and increased neuroinflammation are both associated with deficits in cognitive function, even
      in the absence of neurodegenerative disease. In older adults, decreased cognition is strongly
      associated with the development of AD, increased rates of hospitalization, loss of functional
      independence, and increased mortality rate. Novel methods for preventing cognitive decline
      and neurodegenerative diseases in older adults are needed the world's aging population.

      Current research suggests that nutrients in fruits and vegetables produce strong anti-oxidant
      and anti-proliferative effects. Most Americans are not consuming the minimum recommendations
      of fruits and vegetables per day to receive these benefits. Whole food-based nutritional
      products, such as Fermented Papaya Product (FPP), may provide a healthy alternative for
      individuals. FPP, which is made by bio-fermentation of Carica papaya, has been found to
      enhance antioxidant protection and to decrease DNA damage in healthy older adults.
      Furthermore, if FPP increases cerebral energy metabolism and down-regulates
      neuroinflammation, with resulting effects on cognition, dietary supplementation with FPP may
      have preventative benefits for age-related cognitive conditions, including MCI, AD,
      Parkinson's disease and other neurodegenerative diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design of this research study is to conduct a double-blind, randomized,
      placebo-controlled pilot study to determine whether FPP improves cerebral energy metabolism,
      neuroinflammation, systemic inflammation, cognitive function, fatigue, and health-related
      quality of life in older adults.

      Potential participants will participate in a brief 10 minute phone screening that will
      describe the study. If participants meet initial inclusion/exclusion criteria on the phone
      screen, they will be scheduled for an in-person screening visit. Participants will attend
      five (5) in person visits including one Screening Visit performed individually for each
      potential study participant, and four Assessment Visits (V1-V4). Participants will be asked
      to provide a fasting blood sample that will be utilized to evaluate clinical laboratory
      parameters at the Screening visit and all four assessment visits. The participants will
      complete both a treatment and a placebo condition; therefore, a cross-over design will be
      used. After eight (8) weeks on each of these regimens, participants will be asked to complete
      post-treatment outcome assessments at the University of Florida's Institute on Aging -
      Clinical and Translational Research Building (IOA - CTRB). Following the first post-treatment
      test day (V2), participants will complete a six (6) week washout period and will then return
      to the IOA - CTRB to complete the other study arm. The order the participants receive FPP and
      placebo will be determined through randomization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue</measure>
    <time_frame>Participants received MRS at weeks 0, 8, 14, and 22. Data reported in the outcome measures data table represents difference between pre and post measurement values (post-pre) for each arm.</time_frame>
    <description>Cerebral energy metabolism will be defined by phosphorus magnetic resonance spectroscopy markers of ATP/mitochondrial function in brain tissue (α-ATP, β-ATP, and γ-ATP).
Within-subject crossover design; difference between drug and placebo arms. Treatment duration: weeks 0-8 followed by washout then weeks 14 to 22.
Data reported in the outcome measures data table represents difference between pre and post measurement values (post-pre) for each arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Metabolism - Cerebral Energy</condition>
  <arm_group>
    <arm_group_label>Fermented Papaya Preparation, then granulated sugar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Granulated Sugar, then Fermented Papaya Preparation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fermented Papaya Preparation</intervention_name>
    <description>This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.</description>
    <arm_group_label>Fermented Papaya Preparation, then granulated sugar</arm_group_label>
    <arm_group_label>Granulated Sugar, then Fermented Papaya Preparation</arm_group_label>
    <other_name>FPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Granulated Sugar</intervention_name>
    <description>This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.</description>
    <arm_group_label>Fermented Papaya Preparation, then granulated sugar</arm_group_label>
    <arm_group_label>Granulated Sugar, then Fermented Papaya Preparation</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to participate in all aspects of the study;

          -  Not confined to a wheelchair;

          -  Evidence of cognitive aging based on Montreal Cognitive Assessment score less than or
             equal to 28, but greater than or equal to 23;

          -  Presence of elevated levels of systemic inflammation at screening (C-reactive protein
             levels &gt; 1.0)

          -  Able to swallow study product as directed.

        Exclusion Criteria:

          -  Failure to give consent;

          -  Active treatment for cancer (&lt; 3 years);

          -  Stroke (&lt; 6 mo);

          -  Serious heart condition, peripheral vascular disease, coronary artery disease
             (myocardial infarction&lt;6 mo), Class III, IV Congestive Heart Failure;

          -  Dementia (e.g., Alzheimer's disease)

          -  Severe anemia (Hgb &lt; 8.0 g/dL);

          -  Any blood or bleeding disorders;

          -  Liver or renal disease;

          -  Diabetes;

          -  Severe osteoarthritis;

          -  Anticoagulant therapy (aspirin use is permitted);

          -  Parkinson's disease;

          -  Severe psychiatric disease or psychological disorder (e.g., severe depression,
             bi-polar disorder, schizophrenia) or current use of antipsychotics;

          -  Current use of anabolic medications (e.g., growth hormone or testosterone) or
             anticholinesterase inhibitor (i.e., Aricept);

          -  High amounts of physical activity (i.e., running, bicycling, etc.) &gt; 120 min/week;

          -  Excessive alcohol use (&gt;2 drinks per day);

          -  Use of tobacco products;

          -  Resting heart rate &gt; 120 bpm;

          -  History of significant head injury leading to cognitive impairments;

          -  Visual or hearing impairments that would interfere with testing;

          -  Allergies to papaya or foods with similar compounds (i.e., banana, avocado, kiwi,
             chestnuts, hazel nuts)

          -  Allergy to latex;

          -  Participating in another clinical trial or has received an investigational product
             within 30 days prior to screening/enrollment;

          -  Center for Epidemiological Studies - Depression Scale (CES-D) Score &gt; 20.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Woods, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Flrodia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Institute on Aging</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <results_first_submitted>July 23, 2019</results_first_submitted>
  <results_first_submitted_qc>October 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2019</results_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuroinflammation</keyword>
  <keyword>cognitive function</keyword>
  <keyword>aging adults</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02771366/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Within subject design, total N = 30. Participants complete both arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fermented Papaya Preparation Arm</title>
          <description>Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
        <group group_id="P2">
          <title>Granulated Sugar Arm</title>
          <description>Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Crossover)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Within subject design, all participants complete both arms. Order is randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Fermented Papaya Preparation First Arm</title>
          <description>Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
        <group group_id="B2">
          <title>Granulated Sugar First Arm</title>
          <description>Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.47" spread="6.33"/>
                    <measurement group_id="B2" value="71.93" spread="5.30"/>
                    <measurement group_id="B3" value="73.2" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue</title>
        <description>Cerebral energy metabolism will be defined by phosphorus magnetic resonance spectroscopy markers of ATP/mitochondrial function in brain tissue (α-ATP, β-ATP, and γ-ATP).
Within-subject crossover design; difference between drug and placebo arms. Treatment duration: weeks 0-8 followed by washout then weeks 14 to 22.
Data reported in the outcome measures data table represents difference between pre and post measurement values (post-pre) for each arm.</description>
        <time_frame>Participants received MRS at weeks 0, 8, 14, and 22. Data reported in the outcome measures data table represents difference between pre and post measurement values (post-pre) for each arm.</time_frame>
        <population>26 completed subjects eligible for analysis. Data acquisition errors in 6 subjects reduced the complete sample to 20 (data from 20 subjects with complete data presented in outcome measures table).</population>
        <group_list>
          <group group_id="O1">
            <title>Fermented Papaya Preparation Arm</title>
            <description>Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Granulated Sugar Arm</title>
            <description>Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue</title>
          <description>Cerebral energy metabolism will be defined by phosphorus magnetic resonance spectroscopy markers of ATP/mitochondrial function in brain tissue (α-ATP, β-ATP, and γ-ATP).
Within-subject crossover design; difference between drug and placebo arms. Treatment duration: weeks 0-8 followed by washout then weeks 14 to 22.
Data reported in the outcome measures data table represents difference between pre and post measurement values (post-pre) for each arm.</description>
          <population>26 completed subjects eligible for analysis. Data acquisition errors in 6 subjects reduced the complete sample to 20 (data from 20 subjects with complete data presented in outcome measures table).</population>
          <units>Difference in metabolite amplitude</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frontal A-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".011" spread=".055"/>
                    <measurement group_id="O2" value=".007" spread=".046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal B-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".009" spread=".056"/>
                    <measurement group_id="O2" value=".006" spread=".086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal G-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".020" spread=".065"/>
                    <measurement group_id="O2" value=".013" spread=".057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior A-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.018" spread=".052"/>
                    <measurement group_id="O2" value=".006" spread=".055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior B-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.002" spread=".060"/>
                    <measurement group_id="O2" value="-.014" spread=".058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior G-ATP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".026" spread=".055"/>
                    <measurement group_id="O2" value="-.010" spread=".050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed over 8 weeks during the FPP arm. Adverse events were assessed over 8 weeks during the Granulated Sugar arm. Adverse events were assessed over 6 weeks during the washout period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fermented Papaya Preparation Arm</title>
          <description>Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
        <group group_id="E2">
          <title>Granulated Sugar Arm</title>
          <description>Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken.
Fermented Papaya Preparation: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Granulated Sugar: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Magnetic Resonance Spectroscopy: MRS will be performed during weeks 0, 8, 14, and 22.
Magnetic resonance imaging: MRS will be performed during weeks 0, 8, 14, and 22.</description>
        </group>
        <group group_id="E3">
          <title>Washout Period</title>
          <description>This is the 6 week period between the FPP and Placebo arms.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel blockage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stomach ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Swelling in legs and feet</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dazedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Broken foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Injury occurred outside of study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger/Hostility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Stage 3 Kidney Failure</sub_title>
                <description>Participant had previous kidney problems before study began</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Woods, Ph.D.</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-294-5842</phone>
      <email>ajwoods@phhp.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

